DOI Services Persistent Identifiers for Scholarly Research
You are viewing the preserved copy. Open the article on the journal's website →

International Journal Of Clinical Therapeutics And Medical Research • pp. 1-9

THE ROLE OF NOVEL IMMUNOTHERAPIES IN IMPROVING CLINICAL OUTCOMES ACROSS DIFFERENT TYPES OF CANCER

  • Sana Afzal BS, Department of Computer Science, The Cosmic Degree College (For Women) ,University of Okara

Abstract

Cancer immunotherapy has emerged as a major advancement in modern oncology by utilizing and strengthening the

body's immune system to recognize, target, and destroy malignant cells. Unlike conventional cancer treatments that

primarily act directly on rapidly dividing cells, immunotherapeutic approaches stimulate or redirect immune

responses against specific tumor-associated antigens and immune-regulatory pathways. Recent developments

include immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, tumor-infiltrating

lymphocyte (TIL) therapy, bispecific antibodies, engineered immune-cell therapies, therapeutic cancer vaccines, and

oncolytic viruses. These approaches have demonstrated significant clinical benefits in selected malignancies,

including melanoma, lung cancer, renal cell carcinoma, hematological cancers, and certain solid tumors. This

research article examines the contribution of novel immunotherapies to improving treatment response, disease

control, survival outcomes, and quality of life across different cancer types. It also explores the importance of tumor

biomarkers, personalized treatment strategies, combination therapies, and the tumor microenvironment in

determining therapeutic effectiveness. The study adopts a qualitative descriptive review methodology based on

relevant peer-reviewed literature published between 2024 and 2026. The reviewed evidence indicates that

immunotherapy has expanded treatment opportunities for patients with several previously difficult-to-treat cancers.

However, variations in treatment response, immune-related adverse events, acquired resistance, high treatment

costs, and limited accessibility remain important challenges. The article concludes that continued clinical research,

improved patient selection, and personalized immunotherapeutic strategies are essential for maximizing the benefits

of modern cancer treatment.

Record

Identifier
https://doi-services.com/1168/307
Published
2026-09-16
Version
1
Original
https://studentsconsultancyhome.com/season-2/journal/index.php/ijctmr/article/view/307